Literature DB >> 7710023

The intensive care treatment of convulsive status epilepticus in the UK. Results of a national survey and recommendations.

M C Walker1, S J Smith, S D Shorvon.   

Abstract

Six hundred and ninety-four members of the Intensive Care Society working in the UK were surveyed by postal questionnaire between May and November 1993 to determine their management of convulsive status epilepticus resistant to initial therapy with intravenous diazepam and phenytoin. Four hundred and eight forms were completed and returned (58.8%). The survey revealed that, following failure of initial management, a benzodiazepine infusion (35%) or anaesthetic induction agent (32%) were the preferred second lines of treatment in intensive care units. In paediatric intensive care units, phenobarbitone (31%) was the agent of choice. Most respondents (57%) gave anaesthetic induction agents within 60 min of the start of status epilepticus, the majority choosing thiopentone (82%). Patients were usually monitored using clinical assessment only (45%), except in paediatric intensive care units and specialist neurological or neurosurgical units where the majority used a cerebral function monitor. Only 12% of the respondents were aware of a protocol for status epilepticus in their intensive care units. The most frequently used therapeutic and monitoring strategies in the management of refractory status epilepticus in the UK are insufficient and need re-evaluation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710023     DOI: 10.1111/j.1365-2044.1995.tb15095.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

1.  Convulsive Status Epilepticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

2.  The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists.

Authors:  M Holtkamp; F Masuhr; L Harms; K M Einhäupl; H Meierkord; K Buchheim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

Review 3.  Admission to neurological intensive care: who, when, and why?

Authors:  Robin S Howard; Dimitri M Kullmann; Nicholas P Hirsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 4.  Status epilepticus: an evidence based guide.

Authors:  Matthew Walker
Journal:  BMJ       Date:  2005-09-24

Review 5.  Emergency treatment of acute seizures and status epilepticus.

Authors:  R C Tasker
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

Review 6.  Generalised convulsive status epilepticus: an overview.

Authors:  R Nandhagopal
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

7.  Ketamine to treat super-refractory status epilepticus.

Authors:  Ayham Alkhachroum; Caroline A Der-Nigoghossian; Elizabeth Mathews; Nina Massad; Riva Letchinger; Kevin Doyle; Wei-Ting Chiu; Julie Kromm; Clio Rubinos; Angela Velazquez; David Roh; Sachin Agarwal; Soojin Park; E Sander Connolly; Jan Claassen
Journal:  Neurology       Date:  2020-09-01       Impact factor: 9.910

8.  Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study.

Authors:  Nicolas Gaspard; Brandon Foreman; Lilith M Judd; James N Brenton; Barnett R Nathan; Blathnaid M McCoy; Ali Al-Otaibi; Ronan Kilbride; Ivan Sánchez Fernández; Lucy Mendoza; Sophie Samuel; Asma Zakaria; Giridhar P Kalamangalam; Benjamin Legros; Jerzy P Szaflarski; Tobias Loddenkemper; Cecil D Hahn; Howard P Goodkin; Jan Claassen; Lawrence J Hirsch; Suzette M Laroche
Journal:  Epilepsia       Date:  2013-06-12       Impact factor: 5.864

9.  Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis.

Authors:  Moira Cruickshank; Mari Imamura; Corinne Booth; Lorna Aucott; Carl Counsell; Paul Manson; Graham Scotland; Miriam Brazzelli
Journal:  Health Technol Assess       Date:  2022-03       Impact factor: 4.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.